Skip to main content
Erschienen in: Current Fungal Infection Reports 4/2020

06.08.2020 | Fungal Infections in Transplantation (S Shoham, Section Editor)

Interpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transplant Recipients

verfasst von: Kathryn Dzintars, Lindsey P. Toman

Erschienen in: Current Fungal Infection Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim of this paper is to discuss clinical interactions between the azole antifungals and the commonly used immunosuppressants for the prevention of rejection in solid organ transplant recipients.

Recent Findings

Drug–drug interactions between azole antifungals and immunosuppressants have largely been reported in healthy subjects or the hematopoietic stem cell transplant (HSCT) population. Data is emerging evaluating these interactions in solid organ transplant recipients.

Summary

Drug–drug interactions between azole antifungals and immunosuppressants occur at or near the same magnitude as in healthy subjects or the HSCT population. Factors affecting these drug–drug interactions include the influence of the interacting agents on CYP enzymes, the doses of the drugs administered, and the route of administration of both the azoles and immunosuppressants. Care and caution should be exercised when managing solid organ transplant patients receiving medications from both classes.
Literatur
2.
Zurück zum Zitat Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38–54.PubMedCrossRef Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38–54.PubMedCrossRef
3.
Zurück zum Zitat Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.PubMedCrossRef Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.PubMedCrossRef
4.
Zurück zum Zitat Nivoix Y, Leveque D, Herbrecht R, Koffel J, Beretz L, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet. 2008;47:779–92.PubMedCrossRef Nivoix Y, Leveque D, Herbrecht R, Koffel J, Beretz L, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet. 2008;47:779–92.PubMedCrossRef
5.
Zurück zum Zitat Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017;19:e12751.CrossRef Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017;19:e12751.CrossRef
6.
Zurück zum Zitat • Sparkes T, Lemonovich TL, on behalf of the AST Infectious Diseases Community of Practice. Interactions between anti-infective agents and immunosuppressants – Guidelines from the American Society of Transplantation Infectious Diseases Community Practice. Clin Transplant. 2019;33:e13510 The American Society of Transplantation’s Infectious Diseases subgroup published clinical guidelines for the management of drug–drug interactions between anti-infective agents, including antifungals, and immunosuppressants.PubMed • Sparkes T, Lemonovich TL, on behalf of the AST Infectious Diseases Community of Practice. Interactions between anti-infective agents and immunosuppressants – Guidelines from the American Society of Transplantation Infectious Diseases Community Practice. Clin Transplant. 2019;33:e13510 The American Society of Transplantation’s Infectious Diseases subgroup published clinical guidelines for the management of drug–drug interactions between anti-infective agents, including antifungals, and immunosuppressants.PubMed
7.
Zurück zum Zitat Leopoldo M, Nardulli P, Contino M, Leonetti F, Luurtsema G, et al. An updated review on P-glycoprotein inhibitors. Expert Opin Ther Patents. 2019;29:455–61.CrossRef Leopoldo M, Nardulli P, Contino M, Leonetti F, Luurtsema G, et al. An updated review on P-glycoprotein inhibitors. Expert Opin Ther Patents. 2019;29:455–61.CrossRef
8.
Zurück zum Zitat • Bellman R, Smuskiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45:737–79 Excellent review on the clinical relevance of the pharmacokinetics of the azole antifungals used clinically for the treatment and prevention of invasive fungal infections.CrossRef • Bellman R, Smuskiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45:737–79 Excellent review on the clinical relevance of the pharmacokinetics of the azole antifungals used clinically for the treatment and prevention of invasive fungal infections.CrossRef
9.
Zurück zum Zitat Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. ID Clin N Am. 2016;30:51–83. Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. ID Clin N Am. 2016;30:51–83.
10.
Zurück zum Zitat Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother. 1993;27:427–30.PubMedCrossRef Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother. 1993;27:427–30.PubMedCrossRef
11.
Zurück zum Zitat • He J, Yu Y, Yin C, Liu H, Zou H, et al. Clinically significant drug-drug interaction between tacrolimus and fluconazole in stable renal transplant recipient and literature review. J Clin Pharm Therapeutics. 2020;45:264–9 Clinical data describing the concurrent use of fluconazole and tacrolimus for the management of candida esophagitis in a renal transplant recipient.CrossRef • He J, Yu Y, Yin C, Liu H, Zou H, et al. Clinically significant drug-drug interaction between tacrolimus and fluconazole in stable renal transplant recipient and literature review. J Clin Pharm Therapeutics. 2020;45:264–9 Clinical data describing the concurrent use of fluconazole and tacrolimus for the management of candida esophagitis in a renal transplant recipient.CrossRef
12.
Zurück zum Zitat Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation. 2002;10:1477–8.CrossRef Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation. 2002;10:1477–8.CrossRef
13.
Zurück zum Zitat Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother. 2008;42:1711–6.PubMedCrossRef Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother. 2008;42:1711–6.PubMedCrossRef
14.
Zurück zum Zitat Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs. 2007;67:269–98.PubMedCrossRef Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs. 2007;67:269–98.PubMedCrossRef
15.
Zurück zum Zitat Romero AJ, Le PP, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther. 2002;2001(71):226–34.CrossRef Romero AJ, Le PP, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther. 2002;2001(71):226–34.CrossRef
16.
Zurück zum Zitat Spriet I, Grootaert V, Meyfroidt G, Debaveye Y, Willems L. Switching from intravenous to oral tacrolimus and voriconazole leads to more pronounced drug-drug interaction. Eur J Clin Pharmacol. 2013;69:737–8.PubMedCrossRef Spriet I, Grootaert V, Meyfroidt G, Debaveye Y, Willems L. Switching from intravenous to oral tacrolimus and voriconazole leads to more pronounced drug-drug interaction. Eur J Clin Pharmacol. 2013;69:737–8.PubMedCrossRef
17.
Zurück zum Zitat Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ transplant recipients. Am J Transplant. 2017;17:2372–80.PubMedCrossRef Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ transplant recipients. Am J Transplant. 2017;17:2372–80.PubMedCrossRef
18.
Zurück zum Zitat Ceberio I, Dai K, Devlin SM, Barke JN, Castrol-Malaspina H, et al. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50:438–43.PubMedPubMedCentralCrossRef Ceberio I, Dai K, Devlin SM, Barke JN, Castrol-Malaspina H, et al. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50:438–43.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat • Huppertz A, Ott C, Bruckner T, Foerster KI, Burhenne J, et al. Prolonged-release tacrolimus is less susceptible to interaction with strong CYP3A4 inhibitor voriconazole in healthy volunteers. Clin Pharm Ther. 2019;106:1290–8 Data assessing the extent of a drug–drug interaction between prolonged-release tacrolimus and voriconazole in healthy subjects.CrossRef • Huppertz A, Ott C, Bruckner T, Foerster KI, Burhenne J, et al. Prolonged-release tacrolimus is less susceptible to interaction with strong CYP3A4 inhibitor voriconazole in healthy volunteers. Clin Pharm Ther. 2019;106:1290–8 Data assessing the extent of a drug–drug interaction between prolonged-release tacrolimus and voriconazole in healthy subjects.CrossRef
20.
Zurück zum Zitat VFend®(Voriconazole) [package insert]. Pfizer. New York, NY. May 2011. VFend®(Voriconazole) [package insert]. Pfizer. New York, NY. May 2011.
21.
Zurück zum Zitat Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27:825–34.PubMedCrossRef Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27:825–34.PubMedCrossRef
22.
Zurück zum Zitat Deyo JC, Nicolsen N, Lachiewicz A, Koslowski T. Salvage treatment of mucormycosis post-liver transplant with posaconazole during sirolimus maintenance therapy. J Pharm Practice. 2017;30:261–5.CrossRef Deyo JC, Nicolsen N, Lachiewicz A, Koslowski T. Salvage treatment of mucormycosis post-liver transplant with posaconazole during sirolimus maintenance therapy. J Pharm Practice. 2017;30:261–5.CrossRef
23.
Zurück zum Zitat Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016;76:1647–57.PubMedCrossRef Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016;76:1647–57.PubMedCrossRef
24.
Zurück zum Zitat Groll AH, Desai A, Han D, Howieson C, Kato K, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2016;6:76–85.PubMedPubMedCentralCrossRef Groll AH, Desai A, Han D, Howieson C, Kato K, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2016;6:76–85.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Rivosecchi RM, Clancy CJ, Shields RK, Ensor CR, Shullo MA, et al. Effects of isavuconazole on the plasma concentrations of tacrolimus among solid organ transplant patients. Antimicrobial Agents Chemother. 2017;61:e00970–17.CrossRef Rivosecchi RM, Clancy CJ, Shields RK, Ensor CR, Shullo MA, et al. Effects of isavuconazole on the plasma concentrations of tacrolimus among solid organ transplant patients. Antimicrobial Agents Chemother. 2017;61:e00970–17.CrossRef
26.
Zurück zum Zitat Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation. 1991;52(6):1086–7.PubMedPubMedCentralCrossRef Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation. 1991;52(6):1086–7.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Vasquez EM, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transpl. 2001;15:95–9.CrossRef Vasquez EM, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transpl. 2001;15:95–9.CrossRef
28.
Zurück zum Zitat Pfizer Wyeth Pharmaceuticals LLC. Rapamune (sirolimus) United States prescribing information. PA: Philadelphia; January 2020. Pfizer Wyeth Pharmaceuticals LLC. Rapamune (sirolimus) United States prescribing information. PA: Philadelphia; January 2020.
29.
Zurück zum Zitat Novartis Pharmaceuticals Corporation. Zortress (everolimus) United States prescribing information. NJ: East Hanover; January 2018. Novartis Pharmaceuticals Corporation. Zortress (everolimus) United States prescribing information. NJ: East Hanover; January 2018.
30.
Zurück zum Zitat El-Groudy AE, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine A in kidney transplant recipients: ten-year follow-up. Transplantation. 2004;77(9):1371–6.CrossRef El-Groudy AE, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine A in kidney transplant recipients: ten-year follow-up. Transplantation. 2004;77(9):1371–6.CrossRef
31.
Zurück zum Zitat El-Dahshan KF, Bakr MA, Donia AF, Badr AE, Sobh MA. Ketoconazole-tacrolimus coadministration in kidney transplant recipients; two-year results of a prospective randomized study. Am J Nephrol. 2006;26:293–8.PubMedCrossRef El-Dahshan KF, Bakr MA, Donia AF, Badr AE, Sobh MA. Ketoconazole-tacrolimus coadministration in kidney transplant recipients; two-year results of a prospective randomized study. Am J Nephrol. 2006;26:293–8.PubMedCrossRef
32.
Zurück zum Zitat Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation. 2003;77(3):474–5.CrossRef Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation. 2003;77(3):474–5.CrossRef
33.
Zurück zum Zitat Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, et al. Everolimus versus azathioprine in a cyclosporine and ketoconazole based immunosuppressive therapy in kidney transplant:3-year follow-up of an open-label, prospective, cohort, comparative clinical trial. Transplant Proc. 2010;42:270–2.PubMedCrossRef Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, et al. Everolimus versus azathioprine in a cyclosporine and ketoconazole based immunosuppressive therapy in kidney transplant:3-year follow-up of an open-label, prospective, cohort, comparative clinical trial. Transplant Proc. 2010;42:270–2.PubMedCrossRef
Metadaten
Titel
Interpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transplant Recipients
verfasst von
Kathryn Dzintars
Lindsey P. Toman
Publikationsdatum
06.08.2020
Verlag
Springer US
Erschienen in
Current Fungal Infection Reports / Ausgabe 4/2020
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-020-00404-4

Weitere Artikel der Ausgabe 4/2020

Current Fungal Infection Reports 4/2020 Zur Ausgabe

Current Management of Fungal Infections (S Jacobs, Section Editor)

Management of Mucormycosis

Pediatric Fungal Infections (D Corzo Leon, Section Editor)

Skin Fungal Infections in Children: Diagnostic Challenges

Advances in Diagnosis of Invasive Fungal Infections (O Morrissey, Section Editor)

The Aspergillus Lateral Flow Assay for the Diagnosis of Invasive Aspergillosis: an Update

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.